Analgesic effect of intravenous lidocaïne and its mechanisms in patients suffering from chronic inflammatory bowel disease (IBD) with abdominal pain.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508224-35-01

Enrollment

Registered

2024-07-17

Start date

2024-09-30

Completion date

Unknown

Last updated

2025-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel disease

Brief summary

We hope to be able to reduce the background pain scores and decrease the frequency of hyperalgesia flare-ups, and thus reduce the psychosocial impacts associated in these patients.

Interventions

DRUGLinisol 1 %

DRUGsolution injectable

DRUGNaCl 0

DRUG9 % B. Braun

DRUGsolution pour perfusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
We hope to be able to reduce the background pain scores and decrease the frequency of hyperalgesia flare-ups, and thus reduce the psychosocial impacts associated in these patients.	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026